# Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

> **NCT00884845** · PHASE1 · COMPLETED · sponsor: **PharmaMar** · enrollment: 35 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** PM02734 and erlotinib
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00884845
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884845, "Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00884845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*